CLRBHealthcare · BiotechnologyThe 4 Wall Street analysts covering Cellectar Biosciences, Inc. hold a median 12-month price target of $11 — +825.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 13 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cellectar Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CLRB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +825.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | Ladenburg Thalmann | Assumes | Buy | $10 |
| 10 Mar 2026 | Maxim Group | Upgrade | Buy | — |
| 14 May 2025 | Maxim Group | Downgrade | Hold | — |
| 11 Dec 2024 | Oppenheimer | Downgrade | Perform | — |
| 19 Nov 2024 | Oppenheimer | Maintains | Outperform | — |
| 11 Oct 2024 | Oppenheimer | Reiterates | Outperform | $14 |
| 28 Mar 2024 | Oppenheimer | Reiterates | Outperform | — |
| 28 Mar 2024 | Roth MKM | Maintains | Buy | — |
| 4 Mar 2024 | Roth MKM | Reiterates | Buy | — |
| 4 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 July 2022 | Oppenheimer | Assumes | Outperform | $5.50 |
| 25 Nov 2020 | Brookline Capital | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Initiates | Buy | — |
| 25 Nov 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | Oppenheimer | Initiates | Outperform | — |
| 25 Nov 2020 | Roth Capital | Initiates | Buy | — |
| 1 July 2020 | Oppenheimer | Initiates | Outperform | — |
| 23 June 2020 | Maxim Group | Initiates | Buy | — |
| 13 Sept 2019 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLRB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Cellectar Biosciences, Inc. returned −60.5% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 79% of US stocks
Cheaper than 59% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 11% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cellectar Biosciences, Inc. has a market value of $11.4M and an enterprise value of −$20.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$22.3M.
Free cash flow in the twelve months to 30 June 2026: −$19.5M.
Trailing P/E: −0.1×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Cellectar Biosciences, Inc. employs 11 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cellectar Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cellectar Biosciences held its third-quarter 2026 earnings call on November 10, 2026. The excerpt identifies company executives and conference-call participants but provides no further discussion or results.
Why it matters — The excerpt confirms the timing and participants of CLRB’s quarterly call, but contains no financial or operational details.
Cellectar Biosciences reported third-quarter 2026 financial results and corporate updates. It presented updated data at IWWM supporting its planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia.
Why it matters — The update concerns clinical data supporting Cellectar’s planned regulatory strategy for iopofosine I 131 in WM.
Cellectar Biosciences said it will present three posters on iopofosine I 131 in Waldenström macroglobulinemia at the ASH Annual Meeting, including updated Phase 2b analyses reporting durable responses in heavily pretreated patients and suggesting greater benefit with earlier use. The company also plans to present its Phase 3 trial design; first-patient dosing remains on track for 1Q 2027, and an FDA accelerated-approval filing remains targeted for 1H27.
Why it matters — The presentations will share updated clinical findings and development milestones for Cellectar’s lead candidate in Waldenström macroglobulinemia.
Cellectar Biosciences announced it will report third-quarter 2026 financial results and provide a corporate update on November 10, 2026, at 8:30 a.m. The company will also host a conference call.
Why it matters — CLRB watchers can expect the company’s quarterly results and corporate update on the announced date.
Cellectar Biosciences reported a case study describing a complete response lasting more than eight years in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) after a single administration of iopofosine I 131.
Why it matters — The case provides additional clinical support for Cellectar’s iopofosine I 131 program and its potential utility across B-cell malignancies.
The 4 Wall Street analysts covering Cellectar Biosciences, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Cellectar Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cellectar Biosciences, Inc. 23 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Cellectar Biosciences, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +825.1% from the last close, and Ticker Nerd's factor model ranks Cellectar Biosciences, Inc. 23 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cellectar Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.
Cellectar Biosciences, Inc. returned -60.5% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing targeted cancer therapies and imaging agents.
The most recent item we track (Seeking Alpha, 11 Nov 2026): "Cellectar Biosciences, Inc. (CLRB) Q3 2026 Earnings Call Transcript". Cellectar Biosciences held its third-quarter 2026 earnings call on November 10, 2026. The excerpt identifies company executives and conference-call participants but provides no further discussion or results.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing targeted cancer therapies and imaging agents. The company’s work centers on its proprietary phospholipid drug conjugate platform, which is designed to deliver therapeutic payloads directly to cancer cells while limiting exposure to healthy tissue. Its current portfolio includes radioconjugate and other oncology programs aimed at hematologic malignancies and solid tumors, along with imaging applications that support cancer detection and treatment planning. Cellectar Biosciences also pursues commercialization and research collaborations to advance its drug candidates through development. Headquartered in Florham Park, New Jersey, Cellectar Biosciences operates as a specialized cancer-focused company within the biopharmaceutical sector.
CEO Mr. James V. Caruso · 11 employees · United States · https://www.cellectar.com
